• Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors | Morningstar

    Источник: Buzz FX / 18 сен 2024 09:06:12   America/Chicago

    N/A
Опубликовать